Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 85,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

#11Business Buzz: India's Stock Market Plunge, Intel Vs. Nvidia, and China's Fundraising Frenzy

#12Business Buzz: Nvidia's Stock Split, TotalEnergies' UK Power Play, Tencent's Singapore Shift

#13Business Buzz: ECB's 'Hawkish' Rate Cut, Nvidia's $3 Trillion Market Value, Salesforce AI Center

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Thematic (Sector/Industry)

United states Pharmaceuticals / Thematic (Sector/Industry)

<ul>
<li>GSK faces trial over Zantac cancer claims, risking costly settlements amid CEO successes</li>
<li>Elon Musk accused of insider trading by shareholder, selling $7.5 billion in shares before bad news hit</li>
<li>Beijing's $42 billion housing bailout insufficient to tackle massive crisis, raising trade tension concerns</li>
</ul>


GSK faces trial over Zantac cancer claims, risking costly settlements amid CEO successes
Elon Musk accused of insider trading by shareholder, selling $7.5 billion in shares before bad news hit
Beijing's $42 billion housing bailout insufficient to tackle massive crisis, raising trade tension concerns


#10Business Buzz: Tesla's Insider Trading Allegations, GSK's Legal Woes, and China's Property Crisis